|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DPM2 |
Gene summary for DPM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DPM2 | Gene ID | 8818 |
| Gene name | dolichyl-phosphate mannosyltransferase subunit 2, regulatory | |
| Gene Alias | CDG1U | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | GO:0006066 | UniProtAcc | O94777 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8818 | DPM2 | LZE2T | Human | Esophagus | ESCC | 5.37e-04 | 7.75e-01 | 0.082 |
| 8818 | DPM2 | LZE4T | Human | Esophagus | ESCC | 3.40e-16 | 4.52e-01 | 0.0811 |
| 8818 | DPM2 | LZE5T | Human | Esophagus | ESCC | 1.20e-04 | 3.23e-01 | 0.0514 |
| 8818 | DPM2 | LZE7T | Human | Esophagus | ESCC | 1.14e-06 | 4.88e-01 | 0.0667 |
| 8818 | DPM2 | LZE8T | Human | Esophagus | ESCC | 1.82e-09 | 3.26e-01 | 0.067 |
| 8818 | DPM2 | LZE20T | Human | Esophagus | ESCC | 3.55e-15 | 7.11e-01 | 0.0662 |
| 8818 | DPM2 | LZE22D1 | Human | Esophagus | HGIN | 3.51e-04 | 2.59e-01 | 0.0595 |
| 8818 | DPM2 | LZE22T | Human | Esophagus | ESCC | 1.64e-06 | 6.60e-01 | 0.068 |
| 8818 | DPM2 | LZE24T | Human | Esophagus | ESCC | 2.21e-30 | 7.07e-01 | 0.0596 |
| 8818 | DPM2 | LZE21T | Human | Esophagus | ESCC | 4.77e-04 | 5.40e-01 | 0.0655 |
| 8818 | DPM2 | LZE6T | Human | Esophagus | ESCC | 7.89e-14 | 8.55e-01 | 0.0845 |
| 8818 | DPM2 | P1T-E | Human | Esophagus | ESCC | 4.74e-14 | 7.21e-01 | 0.0875 |
| 8818 | DPM2 | P2T-E | Human | Esophagus | ESCC | 1.13e-56 | 1.11e+00 | 0.1177 |
| 8818 | DPM2 | P4T-E | Human | Esophagus | ESCC | 2.05e-42 | 9.08e-01 | 0.1323 |
| 8818 | DPM2 | P5T-E | Human | Esophagus | ESCC | 3.30e-29 | 5.52e-01 | 0.1327 |
| 8818 | DPM2 | P8T-E | Human | Esophagus | ESCC | 2.17e-63 | 1.25e+00 | 0.0889 |
| 8818 | DPM2 | P9T-E | Human | Esophagus | ESCC | 1.18e-31 | 7.74e-01 | 0.1131 |
| 8818 | DPM2 | P10T-E | Human | Esophagus | ESCC | 1.61e-50 | 8.03e-01 | 0.116 |
| 8818 | DPM2 | P11T-E | Human | Esophagus | ESCC | 6.07e-26 | 1.12e+00 | 0.1426 |
| 8818 | DPM2 | P12T-E | Human | Esophagus | ESCC | 2.43e-27 | 5.91e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003164727 | Esophagus | HGIN | regulation of protein stability | 96/2587 | 298/18723 | 2.21e-16 | 5.76e-14 | 96 |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
| GO:00060668 | Esophagus | ESCC | alcohol metabolic process | 202/8552 | 353/18723 | 7.32e-06 | 7.26e-05 | 202 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00421573 | Esophagus | ESCC | lipoprotein metabolic process | 86/8552 | 135/18723 | 1.78e-05 | 1.57e-04 | 86 |
| GO:00064973 | Esophagus | ESCC | protein lipidation | 62/8552 | 92/18723 | 2.08e-05 | 1.80e-04 | 62 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00421583 | Esophagus | ESCC | lipoprotein biosynthetic process | 64/8552 | 96/18723 | 2.61e-05 | 2.20e-04 | 64 |
| GO:00065063 | Esophagus | ESCC | GPI anchor biosynthetic process | 26/8552 | 32/18723 | 3.97e-05 | 3.21e-04 | 26 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:00065053 | Esophagus | ESCC | GPI anchor metabolic process | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005106 | Esophagus | HGIN | N-Glycan biosynthesis | 17/1383 | 53/8465 | 3.43e-03 | 2.54e-02 | 2.02e-02 | 17 |
| hsa0051013 | Esophagus | HGIN | N-Glycan biosynthesis | 17/1383 | 53/8465 | 3.43e-03 | 2.54e-02 | 2.02e-02 | 17 |
| hsa0051023 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
| hsa0051033 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
| hsa005104 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
| hsa0051011 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
| hsa0051021 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
| hsa0051031 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
| hsa005105 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
| hsa0051012 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
| hsa0051022 | Oral cavity | LP | N-Glycan biosynthesis | 31/2418 | 53/8465 | 4.86e-06 | 4.14e-05 | 2.67e-05 | 31 |
| hsa0051032 | Oral cavity | LP | N-Glycan biosynthesis | 31/2418 | 53/8465 | 4.86e-06 | 4.14e-05 | 2.67e-05 | 31 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DPM2 | SNV | Missense_Mutation | c.21N>T | p.Gln7His | p.Q7H | O94777 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DPM2 | SNV | Missense_Mutation | rs147263320 | c.154N>A | p.Ala52Thr | p.A52T | O94777 | protein_coding | tolerated(0.29) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| DPM2 | SNV | Missense_Mutation | c.88N>A | p.Leu30Ile | p.L30I | O94777 | protein_coding | tolerated(1) | benign(0.006) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |
| DPM2 | SNV | Missense_Mutation | c.88N>A | p.Leu30Ile | p.L30I | O94777 | protein_coding | tolerated(1) | benign(0.006) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DPM2 | SNV | Missense_Mutation | novel | c.76N>A | p.Ala26Thr | p.A26T | O94777 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| DPM2 | SNV | Missense_Mutation | novel | c.193G>A | p.Val65Met | p.V65M | O94777 | protein_coding | deleterious(0.02) | probably_damaging(0.985) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |